logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Coronary Heart Disease

    Medications for Coronary Heart Disease

    FiltersReset Filters
    5 results

    • atorvaliq

      (ATORVALIQ)
      CMP Pharma, Inc.
      Usage: ATORVALIQ is indicated to reduce the risk of cardiovascular events in adults with risk factors for coronary heart disease, type 2 diabetes, and clinically evident coronary heart disease. It also lowers LDL cholesterol in various conditions, including primary hyperlipidemia and familial hypercholesterolemia, as an adjunct to diet or other therapies.

    • fluvastatin sodium

      (Fluvastatin Sodium)
      Lannett Company, Inc.
      Usage: Fluvastatin sodium extended-release tablets are indicated for reducing the risk of coronary revascularization and slowing coronary atherosclerosis in adults with coronary heart disease. They also help lower LDL cholesterol in adults with primary hyperlipidemia and in pediatric patients aged 10 and older with heterozygous familial hypercholesterolemia.

    • lovastatin

      (lovastatin)
      Lupin Pharmaceuticals, Inc.
      Usage: Lovastatin is indicated for lowering total and LDL cholesterol levels as part of a treatment strategy in individuals with dyslipidemia at risk for atherosclerotic vascular disease, including those with coronary heart disease and hypercholesterolemia. It is also used for primary prevention of coronary heart disease in certain populations.

    • simvastatin

      (SIMVASTATIN)
      Lupin Pharmaceuticals, Inc.
      Usage: Simvastatin is indicated for reducing total mortality and coronary heart disease events in high-risk adults, managing cholesterol levels in primary hyperlipidemia and heterozygous familial hypercholesterolemia, and as an adjunct therapy for homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and hypertriglyceridemia.

    • vytorin

      (ezetimibe and simvastatin)
      Organon LLC
      Usage: VYTORIN is indicated as an adjunct to diet for reducing elevated LDL cholesterol in adults with primary hyperlipidemia and pediatric patients (10+ years) with heterozygous familial hypercholesterolemia. It also aids in reducing LDL in adults with homozygous familial hypercholesterolemia and lowers cardiovascular risks in high-risk adults.